LJUBLJANA, Slovenia — Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. “PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world,” said Mark Pleško, CEO of Cosylab. “Our partners have been clear
on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we’ll keep developing it together with the clinical community that helped shape it.” Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engine for particle therapy, which serves as the physical foundation for accurate LET calculation and variable RBE modelling*. Clinical teams
can plan with confidence and can review plans within a single planning workflow. Full control over plan robustness PlanOne™ provides comprehensive user-defined robust optimization, analysis and evaluation. Beyond the worst-case scenario approach, PlanOne™ supports an all-scenario scheme across the full set of user-defined scenarios simultaneously, resulting in treatment plans that reflect physical reality without compromising the plan’s robustness. One environment. The OIS you already have. Contouring, planning, and review take place within a single environment, and purpose-built tools support the demands of proton and heavy-ion
treatment planning. PlanOne™ integrates with existing oncology information systems, helping preserve established workflows while reducing the need for data migration. About Cosylab Cosylab is a software and control systems company headquartered in Ljubljana, Slovenia. With over 20 years of experience and more than 1,000 projects across particle accelerators, radiation therapy devices, and oncology information systems, Cosylab develops complex software for the world’s most technically demanding environments. PlanOne™ V1.0 is Cosylab’s FDA 510(k) cleared treatment planning system for particle therapy. PlanOne™ V1.0 is FDA 510(k) cleared.
Items marked with * are in preparation for regulatory submission or under development; not yet available for sale and/or clinical use in any market. Market availability is subject to regulatory approval. PlanOne is a trademark of Cosylab d.d., registered in the United States and the European Union. View source version on businesswire.com: https://www.businesswire.com/news/home/20260607163098/en/ For more information, contact: Media contact: Petra Balažic, petra.balazic@cosylab.com Product info: cosylab.com/planone, planone@cosylab.com
Cosylab, PlanOne, particle therapy, treatment planning system, FDA 510(k), Monte Carlo, LET calculation, RBE modelling, robust optimization, oncology information systems, proton therapy, heavy-ion therapy
So basically it’s like… cancer planning but with a better computer?
FDA cleared already? That sounds fast. I don’t even know what Monte Carlo dose engine means but it sounds expensive lol.
Wait so is this thing like AI that decides the dose? Because they said “built to grow with AI” and now people are acting like it’s fully automated. Also LET/RBE sounds like something you’d need a physics degree for.
I’m confused—does “unified clinical workflow” mean doctors get less control? Or does it just move the paperwork into one place? My aunt had proton therapy and they were talking about accuracy and worst-case scenarios, so I guess this helps with that. Either way sounds good, just wish they explained it in normal words.